Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.

March 15, 2024

Vol.50 No.11

In Brief

Alexandra Miller named chief of neuro-oncology and co-director of Brain and Spine Tumor Center at NYU Perlmutter

Alexandra Miller, a neurologist and neuro-oncologist specializing in treating primary brain tumors, has been named as the chief of the Division of Neuro-Oncology and co-director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, effective Jan. 29.

January 26, 2024

Vol.50 No.04

Clinical Roundup

Sylvester study shows glioblastoma can mimic healthy neurons

A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into glioblastoma neuron mimicry and potential therapies to prevent treatment resistance.

January 19, 2024

Vol.50 No.03

In Brief

Glenn Lesser named deputy director of the Atrium Health Wake Forest Baptist CCC

Glenn J. Lesser was named deputy director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center.

December 01, 2023

Vol.49 No.44

Funding Opportunities

TGen establishes fellowship program in GBM

The Translational Genomics Research Institute, part of City of Hope, established a fellowship in glioblastoma multiforme research. The Lori Lane/Andrew Spyrow Fellowship honors the lives of Lori Lane and Andrew Spyrow who fought GBM bravely, teaching all of us to experience the joy of life and dedicating their journey to the advancement of treatment improving the quality and longevity of life for those facing this devastating cancer.

December 01, 2023

Vol.49 No.44

Letter To The Editor

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

A letter to the editor by The Philadelphia Inquirer’s James Neff raises concerns about conflicts of interest in a recent Guest Editorial published in The Cancer Letter. The authors and The Cancer Letter editor respond.

October 27, 2023

Vol.49 No.40

Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada

YOU MAY BE INTERESTED IN

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

Alexandra Miller named chief of neuro-oncology and co-director of Brain and Spine Tumor Center at NYU Perlmutter

Sylvester study shows glioblastoma can mimic healthy neurons

Glenn Lesser named deputy director of the Atrium Health Wake Forest Baptist CCC

TGen establishes fellowship program in GBM

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

Renew today!

Subscriber content

Login